Analytik Jena Subsidiary Obtained Approval for Two New Assays
News Jul 01, 2013
AJ Roboscreen, an Analytik Jena company, recently obtained the approval for two new assays for screening of swine sera for PRRSV (porcine reproductive and respiratory syndrome virus) antibodies and for evaluation.
The new ELISA-based tests differentiate into PRRSV Type I (Europe-Type) and Type II (North America-Type).
The ELISA (Enzyme Linked Immunosorbent Assay) is an immunoassay to detect proteins in liquid samples.
"At present PRRSV causes the most important economical loss in pig industry. According to estimates, 70-80 % of all enterprises in Germany are affected by PRRSV. At least 30,000 to 35,000 tests are used for sow and piglet enterprises in Saxony per year; this corresponds to 40 % of all sows in this federal state in Germany. Resulting reproductive problems and pneumonia lead to reduced growth and vulnerability for secondary infection", said Alexander Berka, Manager of the Life Science business unit at Analytik Jena AG.
Infected animals quickly spread PRRSV within a flock via contaminated body fluids.
Losses of 25 € to 250 € per breeding sow and year are estimated. For this reason several vaccination programs are trying to raise immunity of the flocks.
"Effective containment substantially depends on early identification and quick isolation or removal of infected animals", continued Alexander Berka.
Based on a licensing agreement with the Fraunhofer Institute for Cell Therapy and Immunology, Analytik Jena developed the two new assays PRRSV DETECT-ELISA and PRRSV NA/EU TYP-ELISA.
The new ELISAs currently are a unique solution on the market for PRRSV antibody detection and differentiation for effective control and containment of this infectious and economically devastating disease.
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
New Way Found to Boost Immunity in Fighting Cancer and InfectionsNews
Researchers have identified a key new mechanism that regulates the ability of T-cells of the immune system to react against foreign antigens and cancer.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018
EMBL Course: Brillouin Microscopy: Emerging Tool for Probing Mechanical Properties of Living Cells
Jan 17 - Jan 19, 2018